(R)-3-氨基-2-哌啶酮 | 88763-76-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-3-氨基-2-哌啶酮
• 中文别名: R-3-氨基-2-哌啶酮
• 英文名称: (3R)-aminopiperidin-2-one
• 英文别名: (R)-3-aminopiperidin-2-one；(3R)-3-aminopiperidin-2-one
• CAS: 88763-76-2
• 化学式: C₅H₁₀N₂O
• 分子量: 114.147
• InChiKey: YCCMTCQQDULIFE-SCSAIBSYSA-N

物化性质

• 沸点：
  307.5±35.0 °C(Predicted)
• 密度：
  1.071±0.06 g/cm3(Predicted)
• 溶解度：
  DMF: 30 mg/ml,DMSO: 30 mg/ml,乙醇: 10 mg/ml,PBS (pH 7.2): 10 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光干燥密封。

反应信息

• 作为反应物：
  描述：

  (R)-3-氨基-2-哌啶酮 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 18.42h， 生成 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-{3-[4-(5-methylpyrimidin-2-yl)-1-piperazinyl]propyl}-1H-purine-2,6-dione
  参考文献：
  名称：

  取代黄嘌呤类化合物及其制备方法和用途

  摘要：

  本发明公开了取代黄嘌呤类化合物及其制备方法和用途。具体地说，本发明涉及式(I)的化合物及其立体异构体，其药学可接受的盐，其中R1,R2如说明书所述。本发明还涉及包含本发明化合物的药物组合物，本发明化合物在制备用于治疗和/或预防与DPP‑IV活性过高或者与DPP‑IV过度表达有关的疾病或病症的方法的药物中的用途，以及使用本发明化合物治疗相关疾病的方法。本发明化合物具有有效的抑制DPP‑IV的活性。

  公开号：

  CN104211702B
• 作为产物：
  描述：

  D-鸟氨酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成 (R)-3-氨基-2-哌啶酮
  参考文献：
  名称：

  Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part III: Synthesis of potent antagonists with αvβ3/αIIbβ3 dual activity and improved water solubility

  摘要：

  In order to optimize our novel integrin alpha(v)beta(3)/alpha(IIb)beta(3) dual antagonists, spatial screening at the N-terminus was performed. The alpha(v)beta(3) antagonistic activity varied depending on the space that was occupied by the N-terminus, but high potency against alpha(IIb)beta(3) was well maintained. The (3S)-aminopiperidine analogue had the strongest activity against alpha(v)beta(3), and the S isomer at piperidine was more potent than the R isomer. Compounds selected on the basis of SAR analysis of a novel lead compound showed acceptable early absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles and sufficient water solubility for use as infusion drugs. Docking studies with the alpha(v)beta(3) receptor were performed to confirm the SAR findings. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.055

文献信息

• Pyrrolopyrazine Kinase Inhibitors
  申请人：Hendricks Robert Than

  公开号：US20110230414A1

  公开（公告）日：2011-09-22

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R 2 , R 3 , and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I的新型吡咯吡嗪衍生物，其中变量Q、R2、R3和Y的定义如本文所述，这些衍生物抑制JAK和SYK，对于治疗自身免疫和炎症性疾病有用。
• SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS
  申请人：Bayer AG

  公开号：EP3800188A1

  公开（公告）日：2021-04-07

  The present application relates to novel pyrazolopyrimidine derivatives for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases in humans and in animals, especially of proliferative disorders, autoimmune disorders, metabolic and inflammatory disorders characterized by an overreacting immune system, in particular rheumatological disorders, inflammatory skin disorders, cardiovascular disorders, lung disorders, eye disorders, neurological disorders, pain disorders and cancer, in human as well as of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

  本申请涉及用于治疗和/或预防疾病的新的吡唑并嘧啶衍生物，以及将它们用于生产用于治疗和/或预防人类和动物疾病的药物，尤其是增殖性疾病、自身免疫性疾病、代谢和炎症性疾病，这些疾病的特点是免疫系统过度反应，特别是风湿性疾病、炎症性皮肤病、心血管疾病、肺部疾病、眼病、神经系统疾病、疼痛疾病和癌症，在人类中，以及动物的过敏性/或炎症性疾病，特别是异位性皮炎和/或跳蚤过敏性皮炎，尤其是在家养动物中，特别是在狗中。
• Highly enantioselective synthesis of non-natural aliphatic α-amino acids via asymmetric hydrogenation
  作者：Jianjian Ji、Caiyou Chen、Jiayu Cai、Xinrui Wang、Kai Zhang、Liyang Shi、Hui Lv、Xumu Zhang

  DOI：10.1039/c5ob01111f

  日期：——

  hydrogenated in a highly efficient and enantioselective way. Excellent enantioselectivities together with excellent yields were achieved for a series of substrates. An efficient approach for the synthesis of the intermediate of the orally administered anti-diabetic drugs Alogliptin and Linagliptin in the DPP-4 inhibitor class was also developed.

  通过使用铑-双膦配合物作为催化剂，β-烷基（Z）-N-乙酰基脱氢氨基酯以高效和对映选择性的方式平稳氢化。对于一系列底物，获得了优异的对映选择性和优异的产率。还开发了一种合成口服DPP-4抑制剂类抗糖尿病药物阿格列汀和利格列汀的中间体的有效方法。
• Synthesis of bengamide E analogues and their cytotoxic activity
  作者：Thi Dao Phi、Huong Doan Thi Mai、Van Hieu Tran、Van Loi Vu、Bich Ngan Truong、Tuan Anh Tran、Van Minh Chau、Van Cuong Pham

  DOI：10.1016/j.tetlet.2017.03.077

  日期：2017.5

  indicated that the 2′R analogues were generally more cytotoxic than the 2′S analogues. Additionally, several analogues exhibited selective inhibition against various cancer cell lines: compounds 32a and 32b selectively inhibited MCF-7 cells, while 33b and 35b were more sensitive toward Lu-1 and HepG-2, respectively. Notably, some of the synthetic analogues possess cytotoxic activities with IC50 values less

  通过酰胺偶联反应，从相应的聚酮链和氨基酸制备了一系列的苯甲酰胺E类似物。在2-乙基己酸钠的存在下，在微波辐射下成功地实现了α-氨基内酰胺与聚酮化合物内酯环的开环。针对癌细胞系的面板的细胞毒性活性的评估（KB，人肝癌HepG-2，路-1，MCF-7，HL-60和Hela）指出，2' - [R类似物一般比2多的细胞毒性“ š类似物。另外，几种类似物表现出对多种癌细胞系的选择性抑制：化合物32a和32b选择性抑制MCF-7细胞，而33b和35b分别对Lu-1和HepG-2敏感。值得注意的是，某些合成类似物具有细胞毒活性，IC 50值小于1 µM。
• [EN] ANTI-INFLAMMATORY AGENTS<br/>[FR] AGENTS ANTI-INFLAMMATOIRES
  申请人：CAMBRIDGE ENTPR LTD

  公开号：WO2011154696A1

  公开（公告）日：2011-12-15

  Disclosed herein are methods of preventing or treating inflammatory diseases using 3 - aminolactam compounds, each with aromatic "tail groups". Compounds as defined by formulae (I) and (I'), and the medical uses of the compounds, are described herein.

  本文揭示了使用具有芳香性“尾基团”的3-氨基内酰胺化合物预防或治疗炎症性疾病的方法。本文描述了由式(I)和(I')定义的化合物以及这些化合物的医学用途。